{"pmid":32345483,"title":"COVID-19 with Pulmonary Involvement. An Autoimmune Disease of Known Cause.","text":["COVID-19 with Pulmonary Involvement. An Autoimmune Disease of Known Cause.","Reumatol Clin","Fernandez-Gutierrez, Benjamin","32345483"],"journal":"Reumatol Clin","authors":["Fernandez-Gutierrez, Benjamin"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32345483","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.reuma.2020.04.001","weight":0,"_version_":1665441658343260160,"score":8.599203,"similar":[{"pmid":32312654,"title":"COVID-19 Pulmonary Involvement: Is Really an Interstitial Pneumonia?","text":["COVID-19 Pulmonary Involvement: Is Really an Interstitial Pneumonia?","Acad Radiol","Boraschi, Piero","32312654"],"journal":"Acad Radiol","authors":["Boraschi, Piero"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32312654","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.acra.2020.04.010","source":"PubMed","topics":["Diagnosis","Treatment"],"weight":1,"_version_":1664714520040308738,"score":59.437294},{"pmid":32341791,"pmcid":"PMC7174058","title":"Thoughts on COVID-19 and autoimmune diseases.","text":["Thoughts on COVID-19 and autoimmune diseases.","Over the 2 months since coronavirus first appeared in China, cases have emerged on every continent, and it is clear that patients with autoimmune diseases might also be affected. Coronavirus disease 2019 (COVID-19) is a highly contagious viral illness with a mortality rate approaching 2%. Here we discuss the challenges that patients with autoimmune diseases might face and the information on using immunomodulatory therapies like chloroquine, tocilizumab and baricitinib to quench the cytokine storm in patients with very severe COVID-19 pneumonia.","Lupus Sci Med","Askanase, Anca D","Khalili, Leila","Buyon, Jill P","32341791"],"abstract":["Over the 2 months since coronavirus first appeared in China, cases have emerged on every continent, and it is clear that patients with autoimmune diseases might also be affected. Coronavirus disease 2019 (COVID-19) is a highly contagious viral illness with a mortality rate approaching 2%. Here we discuss the challenges that patients with autoimmune diseases might face and the information on using immunomodulatory therapies like chloroquine, tocilizumab and baricitinib to quench the cytokine storm in patients with very severe COVID-19 pneumonia."],"journal":"Lupus Sci Med","authors":["Askanase, Anca D","Khalili, Leila","Buyon, Jill P"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32341791","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1136/lupus-2020-000396","keywords":["autoimmune diseases","cytokines","inflammation"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Chloroquine","tocilizumab","baricitinib"],"topics":["Treatment"],"weight":1,"_version_":1665351883824300032,"score":57.089302},{"pmid":32348045,"title":"[Autoimmune diseases in the context of pandemic COVID-19].","text":["[Autoimmune diseases in the context of pandemic COVID-19].","Patient suffering from autoimmune diseases (AID) typically have an increased risk of infection, which is attributed to the disease itself, but also to immunosuppressive drugs (IS) and comorbidities. During the current COVID-19 outbreak, the way to manage these diseases remains elusive. Limited data is currently available on AID and IS in the context of this new coronavirus infection. To date, there is no evidence to support an increase in complications of COVID-19 in these patients. In addition, certain drugs that are commonly used to treat AID could be part of the therapeutic arsenal used in COVID-19. The purpose of this article is to review the unique aspects of patients with AID during the COVID-19 outbreak.","Rev Med Suisse","Horisberger, Alice","Moi, Laura","Ribi, Camillo","Comte, Denis","32348045"],"abstract":["Patient suffering from autoimmune diseases (AID) typically have an increased risk of infection, which is attributed to the disease itself, but also to immunosuppressive drugs (IS) and comorbidities. During the current COVID-19 outbreak, the way to manage these diseases remains elusive. Limited data is currently available on AID and IS in the context of this new coronavirus infection. To date, there is no evidence to support an increase in complications of COVID-19 in these patients. In addition, certain drugs that are commonly used to treat AID could be part of the therapeutic arsenal used in COVID-19. The purpose of this article is to review the unique aspects of patients with AID during the COVID-19 outbreak."],"journal":"Rev Med Suisse","authors":["Horisberger, Alice","Moi, Laura","Ribi, Camillo","Comte, Denis"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32348045","source":"PubMed","week":"202018|Apr 27 - May 03","topics":["Prevention","Treatment"],"weight":1,"_version_":1665441658245742593,"score":53.77939},{"pmid":32188753,"pmcid":"PMC7082143","title":"COVID-19: Knowns, Unknowns, and Questions.","text":["COVID-19: Knowns, Unknowns, and Questions.","The recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from the Hubei province in China in late 2019 demonstrates the epidemic potential of coronaviruses. The rapid spread of this virus across the world in only 2 months highlights the transmissibility of this family of viruses and the significant morbidity and mortality that they can cause. We highlight the current state of knowledge of coronavirus biology while answering questions concerning the current outbreak of SARS-CoV-2.","mSphere","Weston, Stuart","Frieman, Matthew B","32188753"],"abstract":["The recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from the Hubei province in China in late 2019 demonstrates the epidemic potential of coronaviruses. The rapid spread of this virus across the world in only 2 months highlights the transmissibility of this family of viruses and the significant morbidity and mortality that they can cause. We highlight the current state of knowledge of coronavirus biology while answering questions concerning the current outbreak of SARS-CoV-2."],"journal":"mSphere","authors":["Weston, Stuart","Frieman, Matthew B"],"date":"2020-03-20T11:00:00Z","year":2020,"_id":"32188753","week":"202012|Mar 16 - Mar 22","doi":"10.1128/mSphere.00203-20","keywords":["covid-19","sars","sars-cov-2","coronavirus"],"source":"PubMed","topics":["Mechanism","Treatment","Transmission"],"weight":1,"locations":["Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664640874529685504,"score":51.00445},{"pmid":32310242,"pmcid":"PMC7162640","title":"The Known into the Unknown: Brugada syndrome and COVID-19.","text":["The Known into the Unknown: Brugada syndrome and COVID-19.","JACC Case Rep","Sorgente, Antonio","Capulzini, Lucio","Brugada, Pedro","32310242"],"journal":"JACC Case Rep","authors":["Sorgente, Antonio","Capulzini, Lucio","Brugada, Pedro"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32310242","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jaccas.2020.04.006","keywords":["brugada syndrome","covid-19","sudden cardiac death"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Brugada"],"_version_":1664632501411250177,"score":48.04732}]}